{"id":240960,"date":"2025-09-20T07:59:14","date_gmt":"2025-09-20T07:59:14","guid":{"rendered":"https:\/\/www.europesays.com\/us\/240960\/"},"modified":"2025-09-20T07:59:14","modified_gmt":"2025-09-20T07:59:14","slug":"cialis-to-go-on-sale-in-japan-as-1st-over-the-counter-ed-treatment-drug","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/240960\/","title":{"rendered":"Cialis to go on sale in Japan as 1st over-the-counter ED treatment drug"},"content":{"rendered":"

<\/p>\n


\n
\n\"\"
\n
\n
\n
\n<\/a>
\n
\nThis file photo shows a building housing Japan’s Ministry of Health, Labor and Welfare in Tokyo. (Mainichi) <\/p>\n


\n TOKYO (Kyodo) — The Tokyo-based pharmaceutical company SSP Co. is set to offer Cialis as Japan’s first over-the-counter erectile dysfunction treatment drug. \n<\/p>\n


\n A health ministry panel on Thursday approved the tablet as a non-prescription drug, though purchases can be permitted only after a pharmacist confirms the customer is at least 18 years old. \n<\/p>\n


\n Beginning in May next year, the tablet, whose generic name is tadalafil, will also be available for purchase on the internet after an online briefing by a pharmacist. \n<\/p>\n


\n The regulatory approval comes amid calls for a non-prescription option given the psychological pressure some men feel about seeing a doctor to seek ED treatment, as well as the risk of receiving fraudulent or contaminated drugs in attempts to order the medication from overseas vendors. \n<\/p>\n


\n Possible side effects include hypersensitivity, muscle pain and headache. \n<\/p>\n


\n The same type of ED treatment has been approved as an OTC medicine in Britain and three other European countries, according to the ministry. <\/p>\n","protected":false},"excerpt":{"rendered":" This file photo shows a building housing Japan’s Ministry of…\n","protected":false},"author":3,"featured_media":240961,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[64,210,170,20067,20066,1060,20068,67,132,68],"class_list":{"0":"post-240960","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-business","9":"tag-health","10":"tag-japan","11":"tag-latest-articles","12":"tag-lifestyle-health","13":"tag-medication","14":"tag-the-mainichi","15":"tag-united-states","16":"tag-unitedstates","17":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115235570808729035","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/240960","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=240960"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/240960\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/240961"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=240960"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=240960"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=240960"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}